Literature DB >> 15461866

Comparison between flurbiprofen and its nitric oxide-releasing derivatives HCT-1026 and NCX-2216 on Abeta(1-42)-induced brain inflammation and neuronal damage in the rat.

C Prosperi1, C Scali, M Barba, A Bellucci, M G Giovannini, G Pepeu, F Casamenti.   

Abstract

Brain inflammation is an underlying factor in the pathogenesis of Alzheimers disease (AD). We investigated, in vivo, whether differences exist in the anti-inflammatory and neuroprotective actions of flurbiprofen and its two nitric oxide-donor derivatives, HCT-1026 and NCX-2216, and the ability of these two derivatives to release nitric oxide in the brain. In adult rats injected into the nucleus basalis with preaggregated Abeta(1-42) we investigated glia reaction, the induction of inducible nitric oxide synthase (iNOS), the activation of p38 mitogen-activated protein kinase (p38MAPK) pathway and the number of choline acetyltransferase (ChAT)-positive neurons and, in naive rats we investigated, by microdialysis, cortical extracellular levels of nitrite. Injection of Abeta(1-42) induced iNOS and activation of p38MAPK 7 days after injection and an intense microglia and astrocyte reaction along with a marked reduction in the number ChAT-positive neurons, persisting up to at least 21 days. Flurbiprofen, HCT-1026 and NCX-2216 (15 mg/kg) significantly attenuated the Abeta(1-42)-induced glia reaction, iNOS induction and p38MAPK activation 7 days after treatment and astrocytes reaction 21 days after treatment. On an equimolar basis, HCT-1026 resulted the most active agent in reducing the Abeta(1-42)-induced microglia reaction. The cholinergic cell loss was also significantly reduced by 21 days of HCT-1026 treatment. No differences in body weight were found between the animals treated for 21 days with 15 mg/kg of either HCT-1026 or NCX-2216 and the controls. Oral administration of HCT-1026 (15 mg/kg) or NCX-2216 (100 mg/kg) to naive rats was followed by significant and long lasting increases in cortical nitrite levels. These findings indicate that the addition of a nitric oxide donor potentiates the anti-inflammatory activity of flurbiprofen in a model of brain inflammation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15461866     DOI: 10.1177/039463200401700312

Source DB:  PubMed          Journal:  Int J Immunopathol Pharmacol        ISSN: 0394-6320            Impact factor:   3.219


  5 in total

1.  Inhibition of amyloidogenesis by nonsteroidal anti-inflammatory drugs and their hybrid nitrates.

Authors:  Isaac T Schiefer; Samer Abdul-Hay; Huali Wang; Michael Vanni; Zhihui Qin; Gregory R J Thatcher
Journal:  J Med Chem       Date:  2011-03-15       Impact factor: 7.446

Review 2.  Pharmacokinetics and pharmacodynamics of nitric oxide mimetic agents.

Authors:  Austin Horton; Isaac T Schiefer
Journal:  Nitric Oxide       Date:  2019-01-11       Impact factor: 4.427

3.  NO-flurbiprofen reduces amyloid-beta, is neuroprotective in cell culture, and enhances cognition in response to cholinergic blockade.

Authors:  Samer O Abdul-Hay; Jia Luo; Rezene T Ashghodom; Gregory R J Thatcher
Journal:  J Neurochem       Date:  2009-08-21       Impact factor: 5.372

4.  Nitric oxide-releasing flurbiprofen reduces formation of proinflammatory hydrogen sulfide in lipopolysaccharide-treated rat.

Authors:  Farhana Anuar; Matthew Whiteman; Jia Ling Siau; Shing Erl Kwong; Madhav Bhatia; Philip K Moore
Journal:  Br J Pharmacol       Date:  2006-04       Impact factor: 8.739

5.  Chronic administration of R-flurbiprofen attenuates learning impairments in transgenic amyloid precursor protein mice.

Authors:  Thomas Kukar; Sonya Prescott; Jason L Eriksen; Vallie Holloway; M Paul Murphy; Edward H Koo; Todd E Golde; Michelle M Nicolle
Journal:  BMC Neurosci       Date:  2007-07-24       Impact factor: 3.288

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.